Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

The launch of Mounjaro always raised the risk that it would cannibalise sales of Lilly's own GLP-1 agonist Trulicity (dulaglutide), which is competing head-to-head with Ozempic in the market ...

"Johnson & Johnson and Mitsubishi Tanabe Pharma’s Stelara (ustekinumab) and Eli Lilly and Sumitomo Dainippon Pharma’s Trulicity (dulaglutide) are ranked ninth and tenth,” Sabaratnam says.

Available Ozempic alternatives: dulaglutide (generic Trulicity), Metformin, Rybelsus, Wegovy, and Saxenda Keep in mind that location, eligibility criteria, medical history, and drug shortages may ...

These patents cover combinations of buntanetap with Trulicity (dulaglutide), Via MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Objective—Recent data suggested that sex hormone–binding globulin (SHBG) levels decrease when fat accumulates in the liver and that circulating SHBG may be causally involved in the ...

Despite decades of acknowledging that a loss of insulin-producing pancreatic β-cells is central to the disorder now referred to as type 1 diabetes, the specific roles for genetic susceptibility ...